Researchers from the University of Illinois at Chicago studied coding ambiguities using the subset of hematology and oncology diagnoses to predict the challenges and consequences of the switch for all providers. Researchers selected 120 ICD-9 codes with the highest Medicaid reimbursements among hematology/oncology physicians, and 100 of the University of Illinois Cancer Center’s most-used ICD-9 codes. Researchers then translated the codes into ICD-10 codes and analyzed whether a loss of information occurred in the translation and whether that information loss would have financial consequences for the provider.
“What we found was the transition from ICD-9 to ICD-10 led to significant information loss, affecting about 8 percent of the Medicaid codes and 1 percent of the codes in our cancer clinic,” said Neeta Venepalli, MD, UIC assistant professor of hematology/oncology and the study’s lead author, in a news release.
In terms of financial implications, the researchers found the 39 ICD-9 codes where information was lost in the translation accounted for 2.9 percent of total Medicaid reimbursements and 5.3 percent of the clinic’s billing changes. Researchers concluded the transition could have a very real impact on providers’ finances.
More Articles on ICD-10:
AMA: ICD-10 7 Step Training Checklist
Fitch: ICD-10 Could Hurt Nonprofit Hospitals’ Credit Ratings
Paul Levy: Is ICD-10 Worth the Cost?
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.